GeneOne Life Science, Inc. (011000.KS)
011000.KS Stock Price Chart
Explore GeneOne Life Science, Inc. interactive price chart. Choose custom timeframes to analyze 011000.KS price movements and trends.
011000.KS Company Profile
Discover essential business fundamentals and corporate details for GeneOne Life Science, Inc. (011000.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 2000
Employees
46.00
Website
https://www.genels.comCEO
Young-Keun Park
Description
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
011000.KS Financial Timeline
Browse a chronological timeline of GeneOne Life Science, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Stock split effective on 4 Jun 2024
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 23 Feb 2024
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 15 Nov 2023
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 25 Oct 2023
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
Revenue for the quarter reached ₩11.73B .
Stock split effective on 22 Sept 2023
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 9 Aug 2023
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 18 Jul 2023
Shares were split 6 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2023
EPS came in at -₩171.00 , while revenue for the quarter reached ₩8.33B .
Earnings released on 31 Mar 2023
EPS came in at -₩170.00 , while revenue for the quarter reached ₩7.39B .
Stock split effective on 3 Dec 2021
Shares were split 3 : 2 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 7 Oct 2021
Shares were split 1021 : 1000 , changing the number of shares outstanding and the price per share accordingly.
011000.KS Stock Performance
Access detailed 011000.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.